Explore
Search ClinicalTrials.gov
Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.
Results for “Germany”
Sponsor: Janssen Research & Development, LLC
Dermatitis, Atopic
United States, Argentina, Brazil, Canada, Germany +4 more
Sponsor: Cogent Biosciences, Inc.
Advanced Systemic Mastocytosis (AdvSM) · SM With an Associated Hematologic Neoplasm (SM-AHN) · Mast Cell Leukemia (MCL) · Aggressive Systemic Mastocytosis (ASM)
United States, Australia, Austria, Belgium, Canada +9 more
- A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric CancerRecruiting
Sponsor: Astellas Pharma Global Development, Inc.
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer · Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer · Metastatic Gastric Adenocarcinoma or Cancer · Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
United States, Australia, Belgium, Brazil, Chile +17 more
Sponsor: Janssen Research & Development, LLC
Multiple Myeloma
United States, Australia, Canada, China, France +9 more
Sponsor: Eva Heim
Complex Post-Traumatic Stress Disorder
Germany, Switzerland
- A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic DermatitisActive Not Recruiting
Sponsor: Eli Lilly and Company
Atopic Dermatitis · Eczema
United States, Argentina, Australia, Brazil, Canada +7 more
Sponsor: Janssen Research & Development, LLC
Prostatic Neoplasms, Castration-Resistant
United States, Australia, Belgium, Brazil, Canada +12 more
- Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone MarrowActive Not Recruiting
Sponsor: Y-mAbs Therapeutics
Neuroblastoma
United States, Canada, Denmark, Germany, Hong Kong +4 more
Sponsor: Institut für Pharmakologie und Präventive Medizin
Mitral Regurgitation Functional · Heart Failure · M-TEER
Germany
Sponsor: Universität Münster
Aggressive Diffuse Large B-cell Lymphoma · High-grade B-cell Lymphoma (HGBL) · Follicular Lymphoma (FL) Grade 3B
Germany
- Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)Active Not Recruiting
Sponsor: AstraZeneca
Breast Cancer; HER2-positive; Metastatic
United States, Argentina, Belgium, Brazil, Canada +22 more
Sponsor: ImCheck Therapeutics, an Ipsen company
Solid Tumor, Adult
France, Germany, United Kingdom
Sponsor: AstraZeneca
Newly Diagnosed Multiple Myeloma (NDMM)
United States, Australia, Brazil, Canada, Denmark +10 more
Sponsor: Novartis Pharmaceuticals
Cardiovascular Disease and Lipoprotein(a)
United States, Argentina, Australia, Austria, Belgium +34 more
Sponsor: GlaxoSmithKline
Respiratory Syncytial Virus Infections
United States, Australia, Canada, Germany, Italy +3 more
- A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)Active Not Recruiting
Sponsor: Hoffmann-La Roche
Multiple Sclerosis
United States, Argentina, Australia, Belgium, Brazil +16 more
Sponsor: Novartis Pharmaceuticals
Lupus Nephritis
United States, Argentina, Brazil, China, Colombia +15 more
- Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual MigraineActive Not Recruiting
Sponsor: AbbVie
Menstrual Migraine (MM)
United States, China, Czechia, Germany, Hungary +8 more
Sponsor: Novartis Pharmaceuticals
Relapsing Multiple Sclerosis
Germany
Sponsor: MedSIR
Advanced Breast Cancer · Advanced Breast Carcinoma · Hormone Receptor Positive Breast Carcinoma
Austria, Belgium, France, Germany, Italy +5 more
- A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic DermatitisEnrolling By Invitation
Sponsor: Eli Lilly and Company
Atopic Dermatitis · Eczema
United States, Argentina, Australia, Brazil, Canada +8 more
- REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)Active Not Recruiting
Sponsor: Taiho Oncology, Inc.
Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
United States, Belgium, Brazil, Bulgaria, Canada +18 more
Sponsor: Molecure S.A.
Pulmonary Sarcoidosis
United States, Denmark, France, Germany, Greece +3 more
Sponsor: Novartis Pharmaceuticals
Advanced HR+/HER2- Breast Cancer · Advanced CCNE1-amplified Solid Tumors · Metastatic Castration-resistant Prostate Cancer
United States, Czechia, Denmark, France, Germany +5 more
- A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA NephropathyActive Not Recruiting
Sponsor: Novartis Pharmaceuticals
Primary IgA Nephropathy
United States, Argentina, Australia, Belgium, Brazil +30 more